Former Commerce Department Leaders Urge Biden to Withdraw March-In Proposal
NIST's proposed guidance would deliberately misinterpret a 43-year-old bipartisan law known as the Bayh-Dole Act. That statute has catalyzed
"Never before has any administration, of either party, believed it has the power to relicense patents based on the price of the commercially available products in question," the bipartisan group of former senior officials warned. NIST's unprecedented assertion that a product's price is now a legitimate trigger for invoking march-in rights would turn "our technology transfer system on its head," they continued.
Throughout the six-page letter, the officials refute the legal basis for the NIST guidance while pointing out its many practical flaws.
"We emphasize in the strongest possible terms: the proposed framework poses a major threat to America's prosperity," the letter states.
Signatories of the letter, which was organized by the bipartisan Council for Innovation Promotion, include former
The full letter is available here.
"The Council for Innovation Promotion is honored to lead this distinguished group of former government officials in opposing the march-in proposal," said
About the Council for Innovation Promotion: The Council for Innovation Promotion is a bipartisan coalition dedicated to promoting strong and effective intellectual property rights that drive innovation, boost economic competitiveness, and improve lives everywhere.
Press contact:
[email protected]
202-990-3350
View original content to download multimedia:https://www.prnewswire.com/news-releases/former-commerce-department-leaders-urge-biden-to-withdraw-march-in-proposal-302053501.html
SOURCE Council for Innovation Promotion
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tilley Harley-Davidson Hosts Freedom Revival 70's Classic Motorcycle Show in Statesville, NC on Aug 29, 2026
- LiveNexus Pairs AI Call Center Tools with On-Demand Agents
- Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share